Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michael Kaleko is active.

Publication


Featured researches published by Michael Kaleko.


Journal of Cellular Physiology | 2004

Intraocular gutless adenoviral-vectored VEGF stimulates anterior segment but not retinal neovascularization

Yuji Oshima; Kyoichi Takahashi; Sachiko Oshima; Yoshitsugu Saishin; Yumiko Saishin; Raquel Lima e Silva; Xaoling Liang; P. Seshidhar Reddy; Shanthi Ganesh; Terrence Brann; Gene Liau; Michael Kaleko; Sheila Connelly; Peter A. Campochiaro

Vascular endothelial growth factor (VEGF) and insulin‐like growth factor‐1 (IGF‐1) have been implicated as important stimulatory factors for retinal neovascularization. In this study, we used intraocular gene transfer with gutless adenoviral (AGV) vectors to determine the effect of increased intraocular expression of VEGF, IGF‐1, or sphingosine kinase (SPK), which produces sphingosine‐1‐phosphate, another angiogenic factor. Retinal neovascularization did not occur from intravitreous AGV‐vectored VEGF, IGF‐1, SPK, or combined VEGF and IGF‐1, except occasionally adjacent to the retinal penetration site from the injection. However, corneal and iris neovascularization occurred after 2 weeks in all eyes injected with AGV.VEGF, but not those injected with only AGV.IGF‐1 or AGV.SPK. These data suggest that the superficial capillary bed of the retina is relatively insensitive to VEGF, IGF‐1, or SPK in adult mice, except when combined with retinal trauma. However, AGV‐vectored VEGF is sufficient to consistently cause severe corneal and iris neovascularization. This provides a model for anterior segment neovascularization, which unlike previous models is relatively inexpensive and is not plagued by spontaneous regression, and therefore, may be useful for identification of new treatments.


Archive | 1994

Adenoviral vectors for treatment of hemophilia

Sheila Connelly; Michael Kaleko; Theodore Smith


Archive | 2001

Methods and compositions for treatment of diabetes and related conditions via gene therapy

Shari L. Caplan; Brian R. Boettcher; Eric D. Slosberg; Sheila Connelly; Michael Kaleko; Urvi J. Desai


Archive | 1995

Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents

Bruce C. Trapnell; Soonpin Yei; Allan Mcclelland; Michael Kaleko; Theodore Smith


Archive | 2002

Novel oncolytic adenoviral vectors

Cheng Cheng; Lori Clarke; Sheila Connelly; David L. Ennist; Suzanne Forry-Schaudies; Mario Gorziglia; Paul L. Hallenbeck; Carl Hay; John Leonard Jakubczak; Michael Kaleko; Sandrina Phipps; Patricia C. Ryan; David A. Stewart; Yuefeng Xie


Archive | 2001

Adenovirus particles with mutagenized fiber proteins

John Leonard Jakubczak; Michele Rollence; David A. Stewart; Susan C. Stevenson; Paul L. Hallenbeck; Neeraja Idamakanti; Michael Kaleko; Theodore Smith


Archive | 2002

Novel vector constructs

Lori Clarke; Mario Gorziglia; Paul L. Hallenbeck; John Leonard Jakubczak; Michael Kaleko; Sandrina Phipps


Archive | 2001

Targetting molecules for adenoviral vectors

Jin Gwan Kim; Theodore Smith; Susan C. Stevenson; Michael Kaleko


Archive | 1998

Adenoviral vectors for enhanced gene expression

Sheila Connelly; Michael Kaleko; Theodore Smith


Archive | 2016

BETA-LACTAMASE FORMULATIONS AND USES THEREOF

Andrew Bristol; Michael Kaleko; Sheila Connelly

Collaboration


Dive into the Michael Kaleko's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Bruce C. Trapnell

Cincinnati Children's Hospital Medical Center

View shared research outputs
Top Co-Authors

Avatar

Jennifer A. Maynard

University of Texas at Austin

View shared research outputs
Researchain Logo
Decentralizing Knowledge